227 related articles for article (PubMed ID: 10952785)
1. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.
Webley SD; Hardcastle A; Ladner RD; Jackman AL; Aherne GW
Br J Cancer; 2000 Sep; 83(6):792-9. PubMed ID: 10952785
[TBL] [Abstract][Full Text] [Related]
2. The ability to accumulate deoxyuridine triphosphate and cellular response to thymidylate synthase (TS) inhibition.
Webley SD; Welsh SJ; Jackman AL; Aherne GW
Br J Cancer; 2001 Aug; 85(3):446-52. PubMed ID: 11487279
[TBL] [Abstract][Full Text] [Related]
3. Small interfering RNA-mediated suppression of dUTPase sensitizes cancer cell lines to thymidylate synthase inhibition.
Koehler SE; Ladner RD
Mol Pharmacol; 2004 Sep; 66(3):620-6. PubMed ID: 15322254
[TBL] [Abstract][Full Text] [Related]
4. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
5. Expression of uracil DNA glycosylase (UDG) does not affect cellular sensitivity to thymidylate synthase (TS) inhibition.
Welsh SJ; Hobbs S; Aherne GW
Eur J Cancer; 2003 Feb; 39(3):378-87. PubMed ID: 12565992
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of human acute leukemia cell line resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor.
Kobayashi H; Takemura Y; Miyachi H
Cancer Chemother Pharmacol; 1998; 42(2):105-10. PubMed ID: 9654109
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
Curtin NJ; Harris AL; Aherne GW
Cancer Res; 1991 May; 51(9):2346-52. PubMed ID: 2015598
[TBL] [Abstract][Full Text] [Related]
8. Comparison of thymidylate synthase (TS) protein up-regulation after exposure to TS inhibitors in normal and tumor cell lines and tissues.
Welsh SJ; Titley J; Brunton L; Valenti M; Monaghan P; Jackman AL; Aherne GW
Clin Cancer Res; 2000 Jun; 6(6):2538-46. PubMed ID: 10873110
[TBL] [Abstract][Full Text] [Related]
9. Structure/function analysis of a dUTPase: catalytic mechanism of a potential chemotherapeutic target.
Harris JM; McIntosh EM; Muscat GE
J Mol Biol; 1999 Apr; 288(2):275-87. PubMed ID: 10329142
[TBL] [Abstract][Full Text] [Related]
10. The role of dUTPase and uracil-DNA repair in cancer chemotherapy.
Ladner RD
Curr Protein Pept Sci; 2001 Dec; 2(4):361-70. PubMed ID: 12374095
[TBL] [Abstract][Full Text] [Related]
11. dUTPase and uracil-DNA glycosylase are central modulators of antifolate toxicity in Saccharomyces cerevisiae.
Tinkelenberg BA; Hansbury MJ; Ladner RD
Cancer Res; 2002 Sep; 62(17):4909-15. PubMed ID: 12208740
[TBL] [Abstract][Full Text] [Related]
12. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL
Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer.
Wilson PM; LaBonte MJ; Lenz HJ; Mack PC; Ladner RD
Mol Cancer Ther; 2012 Mar; 11(3):616-28. PubMed ID: 22172489
[TBL] [Abstract][Full Text] [Related]
14. Resistance to fluorodeoxyuridine-induced DNA damage and cytotoxicity correlates with an elevation of deoxyuridine triphosphatase activity and failure to accumulate deoxyuridine triphosphate.
Canman CE; Lawrence TS; Shewach DS; Tang HY; Maybaum J
Cancer Res; 1993 Nov; 53(21):5219-24. PubMed ID: 8221659
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/pharmacodynamic study of ZD9331, a nonpolyglutamatable inhibitor of thymidylate synthase, in a murine model following two curative administration schedules.
Aherne GW; Hardcastle A; Ward E; Dobinson D; Crompton T; Valenti M; Brunton L; Jackman AL
Clin Cancer Res; 2001 Sep; 7(9):2923-30. PubMed ID: 11555611
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells.
Mauritz R; Bekkenk MW; Rots MG; Pieters R; Mini E; van Zantwijk CH; Veerman AJ; Peters GJ; Jansen G
Clin Cancer Res; 1998 Oct; 4(10):2399-410. PubMed ID: 9796971
[TBL] [Abstract][Full Text] [Related]
17. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates.
Longley DB; Boyer J; Allen WL; Latif T; Ferguson PR; Maxwell PJ; McDermott U; Lynch M; Harkin DP; Johnston PG
Cancer Res; 2002 May; 62(9):2644-9. PubMed ID: 11980662
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase inhibitors.
Touroutoglou N; Pazdur R
Clin Cancer Res; 1996 Feb; 2(2):227-43. PubMed ID: 9816165
[TBL] [Abstract][Full Text] [Related]
19. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
Sakoff JA; Howitt IJ; Ackland SP; McCluskey A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):225-32. PubMed ID: 14648018
[TBL] [Abstract][Full Text] [Related]
20. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours.
Jackman AL; Melin CJ; Kimbell R; Brunton L; Aherne GW; Theti DS; Walton M
Biochim Biophys Acta; 2002 Jul; 1587(2-3):215-23. PubMed ID: 12084463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
